SUMMIT, NJ ( TheStreet) -- Celgene: ( CELG) Beat and raise again, but in-line sales of the cancer drug Revlimid may disappoint. Celgene's adjusted earnings rose by a better-than-expected 36% in the third quarter, driven by strong drug sales and a lower share count. Sales of the multiple myeloma drug Revlimid totaled $820 million, in line with consensus of around $818 million. Like it did after the second quarter, Celgene once again raised financial guidance above current consensus for the remainder of the year to adjusted earnings between $3.78 and $3.80 per share from adjusted earnings in the range of $3.45 to $3.55 per share. The company also raised guidance for total revenue to a range of $4.8 billion to $4.85 billion from $4.6 billion to $4.7 billion The new top-line forecast also includes refined guidance for Revlimid sales in the range of $3.2 billion to $3.25 billion. The 28% year-over-year increase in Revlimid sales were essentially in line with Street expectations, so Celgene's outperformance in this September quarter was largely driven by better-than-expected sales of Abraxane ($114 million) and Vidaza ($191 million.) Celgene's share count of 460 million was also slightly lower than expectations, boosting earnings per share. Investors are accustomed to Revlimid smashing through consensus expectations, which didn't happen in the third quarter. This likely explains why Celgene shares are trading down 3% to $64.40 in Thursday's pre-market. Net income in the September quarter rose to $373 million, or 81 cents per share, from $281 million, or 60 cents a share, one year ago. The boost was aided by the acquisition of Abraxis BioScience last year. On an adjusted basis, Celgene earned $1.02 cents per share in the quarter, up 36% year over year and topping analysts' average adjusted earnings estimate of 95 cents a share. Total revenue in the quarter rose 37% year over year to $1.25 billion. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.